Theriva Biologics reports $18.3M cash as of Q1 2024, VIRAGE enrollment on track for Q3 completion

Theriva Biologics, Inc.

2024-Q1 EPS reported -$0.30

Cash and cash equivalents $18.3M at March 31, 2024, expected to fund operations into Q1 2025.
R&D expenses $3.5M in Q1 2024, up 16% YoY due to clinical trial costs.
VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.
Positive topline data from Phase 1 trial of VCN-01 in pediatric refractory retinoblastoma – study committee deemed results positive.
Licensing discussions ongoing for SYN-020 intestinal alkaline phosphatase asset.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-057689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.